Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

View Full Paper
Ask AI
Bookmark
Share

Authors

SASameem AbedinVBVictor BaidooRJRichard J. Jones

Discussion

Loading...

Member takes

Overview

Post hoc analysis reveals gilteritinib did not improve survival in older patients, indicating further toxicity reduction strategies are needed.

Key Points

  • Evaluate the effect of gilteritinib maintenance on survival outcomes in older adults with FLT3-ITD mutated AML after alloHCT.
  • Post hoc analysis of randomized BMT CTN 1506 trial data
  • Inclusion of patients aged ≥60 years
  • Primary endpoint was relapse-free survival (RFS) and overall survival (OS) assessments
  • No significant differences in RFS and OS between gilteritinib and placebo groups
  • Lower relapse rates with gilteritinib but higher non-relapse mortality
  • Adverse events were the main reason for discontinuation of gilteritinib therapy.

Cite This Study

Abedin et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfbehttps://doi.org/10.1182/blood-2025-170
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study2025
  2. 2Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis2025
  3. 3Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations2026
  4. 4Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib2025
  5. 5Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML2026